vi-va
SENIOR MEMBER
- Joined
- Jan 23, 2019
- Messages
- 6,475
- Reaction score
- 3
- Country
- Location
Sinovac Ready to Distributes 50 Million CoronaVac for Indonesia
By
Desk Editor Insider
-
August 22, 2020
Chinese pharmacy firm, Sinovac Biotech, has committed to provide 50 million doses of a COVID-19 vaccine candidate to Indonesian government starting November to March - Photo by MoFA Office
JAKARTA (TheInsiderStories) – Chinese pharmacy firm, Sinovac Biotech, has committed to provide 50 million doses of a COVID-19 vaccine candidate to Indonesian government starting November to March. As reported, the state-run, PT Biofarma has signed the deal with Sinovac on Wednesday (08/19).
According to foreign minister, Retno Marsudi, both parties has signed the CoronaVac purchases in the fourth quarter of this year to first quarter of 2021 and then Bio Farma would get priority access until end next year. Last week, President Joko Widodo has witnessed the phase III trials for Sinovac’ CoronaVac involving 1,620 volunteers.
The state run drug-makers is involved in the development of the vaccine and has said the country will have capacity to produce 250 million doses of the vaccines by the end of 2020. Widodo targeting Indonesia could produces COVID-19 vaccines on the firs semester of 2021.
“For three months we developed our own vaccine with brand Merah Putih. Its estimated that this can be completed in mid-2021 by various parties and open themselves to collaborating with SINOVAC, Uni Arab Emirates, South Korea and others to be able to vaccinate all Indonesian people,” he told reporters during his official visit to West Java province on August 11.
On July 21, a total of 2,400 vaccines from Sinovac have arrived at Bio Farma. According to the CEO, Honesti Basyir, the clinical trial of the vaccine is scheduled to run for six months, so it is targeted to be completed in January 2021.
“If the clinical trial of the vaccine phase three goes well, then Bio Farma will produce it in the first quarter of 2021,” he told reporters, by adding the company,have prepared production facilities at Bio Farma with the maximum production capacity is 250 million doses.
Basyir explained, the vaccines that came on last July, still require several more stages and must be passed include testing Biofarma‘ laboratory and several other licenses. This vaccine clinical trial will take as many as 1,620 subjects with an age range between 18 and 59 years and certain criteria.
He said, the reason for choosing Sinovac as a partner caused the vaccine manufacturing method used same with the company’ current competences. With this inactivation method, the pharmacy firm already has experience in making vaccines such as the Pertussis vaccine.
The remainder of the vaccine will be used for laboratory tests in several laboratories including Bio Farma and the National Food and Drug Testing Center. In the clinical trial of the vaccine, Bio Farma acted as a sponsor, collaborating with various parties, including the Indonesian Health Research and Development Agency of the ministry of health, as medical advisor and implementing neutralization antibody titer tests.
Beside, the producer also collaborates with National Agency of Drug and Food Control as the regulator and of course with the Padjajaran University as an institution that has experience in implementing clinical trials of vaccines circulating in Indonesia.
The development of the vaccine is one of five scenarios for Bio Farma, in dealing with the spread of the SARS COV2 virus, including production of realtime polymerase chain reaction, convalescent plasma therapy, mobile BSL 3 laboratories, and manufacturing viral transport media.
theinsiderstories.com
By
Desk Editor Insider
-
August 22, 2020
Chinese pharmacy firm, Sinovac Biotech, has committed to provide 50 million doses of a COVID-19 vaccine candidate to Indonesian government starting November to March - Photo by MoFA Office
JAKARTA (TheInsiderStories) – Chinese pharmacy firm, Sinovac Biotech, has committed to provide 50 million doses of a COVID-19 vaccine candidate to Indonesian government starting November to March. As reported, the state-run, PT Biofarma has signed the deal with Sinovac on Wednesday (08/19).
According to foreign minister, Retno Marsudi, both parties has signed the CoronaVac purchases in the fourth quarter of this year to first quarter of 2021 and then Bio Farma would get priority access until end next year. Last week, President Joko Widodo has witnessed the phase III trials for Sinovac’ CoronaVac involving 1,620 volunteers.
The state run drug-makers is involved in the development of the vaccine and has said the country will have capacity to produce 250 million doses of the vaccines by the end of 2020. Widodo targeting Indonesia could produces COVID-19 vaccines on the firs semester of 2021.
“For three months we developed our own vaccine with brand Merah Putih. Its estimated that this can be completed in mid-2021 by various parties and open themselves to collaborating with SINOVAC, Uni Arab Emirates, South Korea and others to be able to vaccinate all Indonesian people,” he told reporters during his official visit to West Java province on August 11.
On July 21, a total of 2,400 vaccines from Sinovac have arrived at Bio Farma. According to the CEO, Honesti Basyir, the clinical trial of the vaccine is scheduled to run for six months, so it is targeted to be completed in January 2021.
“If the clinical trial of the vaccine phase three goes well, then Bio Farma will produce it in the first quarter of 2021,” he told reporters, by adding the company,have prepared production facilities at Bio Farma with the maximum production capacity is 250 million doses.
Basyir explained, the vaccines that came on last July, still require several more stages and must be passed include testing Biofarma‘ laboratory and several other licenses. This vaccine clinical trial will take as many as 1,620 subjects with an age range between 18 and 59 years and certain criteria.
He said, the reason for choosing Sinovac as a partner caused the vaccine manufacturing method used same with the company’ current competences. With this inactivation method, the pharmacy firm already has experience in making vaccines such as the Pertussis vaccine.
The remainder of the vaccine will be used for laboratory tests in several laboratories including Bio Farma and the National Food and Drug Testing Center. In the clinical trial of the vaccine, Bio Farma acted as a sponsor, collaborating with various parties, including the Indonesian Health Research and Development Agency of the ministry of health, as medical advisor and implementing neutralization antibody titer tests.
Beside, the producer also collaborates with National Agency of Drug and Food Control as the regulator and of course with the Padjajaran University as an institution that has experience in implementing clinical trials of vaccines circulating in Indonesia.
The development of the vaccine is one of five scenarios for Bio Farma, in dealing with the spread of the SARS COV2 virus, including production of realtime polymerase chain reaction, convalescent plasma therapy, mobile BSL 3 laboratories, and manufacturing viral transport media.
Sinovac Ready to Distributes 50 Million CoronaVac for Indonesia - The Insiders Stories
JAKARTA (TheInsiderStories) – Chinese pharmacy firm, Sinovac Biotech, has committed to provide 50 million doses of a COVID-19 vaccine candidate to Indonesian government starting November to March. As reported, the state-run, PT Biofarma has signed the deal with Sinovac on Wednesday (08/19)...
theinsiderstories.com
